The interim president and CEO, David D. Stevens, will remain chairman of the Board. Mr. Palmisano most recently served as president and CEO of ev3, a global endovascular device company, where he was able to triple the company’s market capitalization during his two-year tenure.
The company’s compensation committee of its board of directors has approved a stock option in addition to regular compensation to Mr. Palmisano.
Related Articles on Orthopedic Device Companies:
DJO Global Launches New Technology to Combat Knee Pain
BioMedGPS Launches SmartTRAK Shoulder Recon Module
42 Orthopedic and Spine Devices Receive FDA 510(k) Clearance in August
